BioNxt Provides Update on Sublingual Drug Delivery Pipeline

BioNxt Solutions Inc., based in Vancouver, has released an update on its sublingual thin-film drug delivery pipeline. The company is advancing its programs, focusing on drugs like Cladribine for multiple sclerosis and expanding into autoimmune diseases. Additionally, they are progressing with Everolimus for organ transplantation and oncology, and have launched a Semaglutide program targeting metabolic diseases.

CEO Hugh Rogers stated that the goal is to build a pharmaceutical platform enhancing existing therapies. BioNxt is strengthening its intellectual property (IP) portfolio, with patents secured in Europe and Eurasia. In the U.S., the company’s patent application is under accelerated examination.

BioNxt continues exploring strategic commercialization opportunities and is preparing for clinical evaluations. Their efforts aim to maximize the long-term value of their proprietary technology.